Free Shipping on Orders over $200
Unlock 10% Off with Email Signup
Same-Day Shipping Before 3 PM EST
Dispatched Within 24 Hours
Referenced in Human Studies
Third-Party COA Verified
Sourced from Trusted Labs in EU
Scientific Advisory Oversight
Tirzepatide is a synthetic peptide engineered to act as a dual agonist of the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This novel incretin mimetic is under investigation for its role in modulating glucose metabolism and energy balance, making it a focal point in current metabolic disease research.
Structurally based on a 39-amino-acid sequence, tirzepatide incorporates both non-natural amino acids and fatty acid side chains to enhance stability and pharmacokinetic profile. This allows for once-weekly administration in clinical contexts. Its unique dual-receptor activity distinguishes it from mono-agonists such as semaglutide or liraglutide.
Applications:
This peptide is intended for use in preclinical studies, receptor binding assays, mechanistic evaluations, and metabolic pathway elucidation. It is not for human consumption, therapeutic use, or diagnostic procedures.
Key Research Areas:
Our local team are here to help
Have more questions about peptide research? You’re not alone. Explore our Frequently Asked Questions for quick answers—or head to the Knowledge Base to explore study areas, calculators, and protocol guides.
Tirzepatide is studied as a dual GIP and GLP-1 receptor agonist, often in the context of insulin sensitivity, weight regulation, and metabolic signaling.
It’s typically studied weekly in long-term experiments focused on metabolic outcomes.
Keep refrigerated after reconstitution and protect from direct heat and sunlight.
